INTRODUCTION AND OBJECTIVES: Recent institutional series suggest that diabetes mellitus (DM) as well as the DM medication metformin may be associated with adverse outcomes in various malignancies, including non-muscle invasive bladder cancer (NMIBC). We set out to evaluate the relationship between DM and metformin use on disease progression and disease specific survival (DSS) in a cohort of Medicare beneficiaries with NMIBC undergoing intravesical Bacillus Calmette-Guerin (BCG) therapy.
INTRODUCTION AND OBJECTIVES: Recent institutional series suggest that diabetes mellitus (DM) as well as the DM medication metformin may be associated with adverse outcomes in various malignancies, including non-muscle invasive bladder cancer (NMIBC). We set out to evaluate the relationship between DM and metformin use on disease progression and disease specific survival (DSS) in a cohort of Medicare beneficiaries with NMIBC undergoing intravesical Bacillus Calmette-Guerin (BCG) therapy.
METHODS: Using the Surveillance, Epidemiology, and End Results (SEER) Medicare database, we identified patients with high-risk NMIBC who received at least one dose of intravesical BCG. We defined disease progression as receipt of cystectomy, systemic chemotherapy, radiation, SEER stage progression and/or disease specific death. The Diabetic Comorbidity Severity Index was used to define DM severity as mild (0-1 comorbidity) and severe (>2 comorbidities). The relationship between DM severity, disease progression, and DSS was evaluated using the Kaplan-Meier method and multivariable Cox proportional hazards models adjusting for age, race, gender, pathologic stage, and BCG treatment (>/[5 doses vs <5 doses). A subset analysis was then performed on DM patients with Medicare part D coverage to evaluate the prognostic impact of metformin therapy on NMIBC outcomes. RESULTS: Our cohort consisted of 8,774 patients, of which 2,546 had mild DM and 1,017 had severe DM with a median follow-up of 39 months. In adjusted cox proportional hazards models, patients with severe DM had significantly increased risk of disease progression (HR 1.17, 95% CI 1.00 -1.38) and worse DSS (HR 1.21, 95% CI 1.01 -1.45) vs. controls, while mild DM was associated with significantly improved DSS (HR 0.87, 95% CI 0.75 -1.00) but not progression (HR 1.08, 95% CI 0.95-1.22) vs. controls (see Figure) . Metformin use was observed in 1,136 patients accounting for 54% of mild DM patients and 43% of severe DM patients. On sub-analyses, receipt of at least one year of metformin therapy was associated with significantly improved DSS (HR 0.43, 95% CI 0.18 -1.00) in patients with severe DM, but patients with mild DM had no significant difference (HR 0.67, .
CONCLUSIONS: Medicare beneficiaries with NMIBC and severe DM are at increased risk of disease progression and disease specific death compared to controls. Long-term use of metformin in this population of DM patients may help reverse the negative impact of severe DM on NMIBC outcomes. Further study into the role of DM and metformin on NMIBC outcomes is needed. 
INTRODUCTION AND OBJECTIVES:
Intravesical BCG with maintenance is recommended for patients with high-risk non-muscle invasive bladder cancer (NMIBC). However, there remains no bladder sparing option in patients with persistent or early recurrent disease following adequate BCG treatment. We report oncological outcomes of patients with BCG unresponsive disease who were treated with conductive chemohyperthermia (CHT). Vol. 201, No. 4S, Supplement, Friday, May 3, 2019 THE JOURNAL OF UROLOGY Ò e229 METHODS: We utilised a multicentre European retrospective patient cohort of patients treated with the Combat BRS system. Each treatment instillation comprised of MMC with hyperthermia delivered at 43 C over 60 minutes. BCG-unresponsive NMIBC (urothelial carcinoma) was defined as papillary disease AE carcinoma in situ (CIS) within 12 months of last instillation of adequate BCG, or recurrent high grade papillary disease within 6 months of last instillation of adequate BCG therapy, or stage T1 disease at first 3 month cystoscopy following induction BCG. Primary endpoint was the 12-month recurrence-free survival (RFS) and the progression-free survival (PFS).
RESULTS: A total of 87 patients from 14 European institutions met the criteria for BCG-unresponsive disease. Median patient age was 73.3 years (64.0-79.1) with male patients comprising of 77 patients (88.5%). A total of 23 patients (26.4%) had CIS only disease, 52 patients (59.8%) with papillary only disease and 12 patients (13.8%) with concurrent CIS and papillary disease. Of the 64 patients with papillary disease, 35 patients (54.7%) had Ta and 29 patients (45.3%) T1 NMIBC. Sixty six patients (75.9%) had high-risk disease. With a median follow-up of 15 (IQR: 8-29) months, 44 patients developed disease recurrence. RFS at 12 months was 55% and at 24 months was 48%. PFS at 24 months was 95%. In patients with CIS disease, 6-month complete response rate was 57% and only one patient had disease progression.
CONCLUSIONS: BCG-unresponsive NMIBC patients who are treated with CHT delivered using the Combat BRS system had a 24-month DFS of 48% and PFS of 95%. CHT may be an option in NMIBC patients who are unresponsive to BCG.
Source of Funding: none

PD13-11 UP-DATE OF PATHOLOGICAL OUTCOME AND SUBJECTIVE DEFINITION OF FAILURE FOR PATIENTS UNDER ACTIVE SURVEILLANCE FOR RECURRENT LOW-RISK NON-MUSCLE INVASIVE BLADDER CANCER: RESULT FROM BLADDER CANCER ITALIAN ACTIVE SURVEILLANCE (BIAS) PROJECT
Rodolfo Hurle, Paolo Casale, Alberto Saita, NicoloMaria Buffi, Giovanni Lughezzani, Vittorio Fasulo, Davide Maffei, Marco Paciotti, Giulio Bevilacqua, Luigi Domanico, Silvia Zandegiacomo, Massimo Lazzeri*, Giorgio Guazzoni, Rozzano, Italy INTRODUCTION AND OBJECTIVES: Active surveillance (AS) has been showed to be feasible and effective in a sub-set of patients with recurrent Low-Grade Non-Muscle Invasive Bladder Cancer (LG-NMIBC). The aim of this study is to up-date the clinical outcome and investigate the pathological results of patients who failed to remain under AS and required an endoscopic resection.
METHODS: This is a prospective observational cohort study of patients with a previous pathologically confirmed LG NMIBC, who experienced recurrence during follow-up and accepted to undergo AS (protocol ICH/1390: Active surveillance for non-muscle invasive bladder cancer -Bladder Cancer Italian Active Surveillance -BIAS project). AS monitoring consisted of cytology and in-office flexible cystoscopy every 3 months for the first year, and then every six months annually. The primary end-point was to investigate the pathological results of patients who failed to remain in AS according to previous published criteria. The secondary outcome was to up-date the clinical results of our previous series. Data were complemented by descriptive statistical analysis and univariable and multivariable proportional hazard Cox regression.
RESULTS: Overall 167 patients, for 181 AS events, were included. Sixty-one (33.7%) events over 181 were deemed to require treatment (TURBT) because positive cytology (#10), gross-haematuria (#11), increases of number (#15), of size (#17) or both (#8). The median time on AS was 14 months . Pathological specimens from failures did not show any malignancy in 20 cases.
Negative histopathology resulted in urothelial hyperplasia and oedema, submucosal vascular ectasia, mucosal erosion, polypoid cystitis, von Brunn nests hyperplasia and squamous metaplasia. Time from first TUR to AS start was inversely associated with progression free survival (HR 0.97, 95% CI 0.96-1.00, p[0.024).
CONCLUSIONS: AS might be a reasonable strategy in patients presenting with small LG pTa/pT1a recurrent bladder tumours. About 30% of patients deemed failures did not present any neoplastic lesion. Further studies and new biomarkers are mandatory to avoid unnecessary TURBT. The gold standard method used to detect and monitor bladder cancer is cystoscopy, which leads to high diagnostic costs and a high patient burden. The currently available non-invasive approaches either show unsatisfying sensitivity in low-grade tumors or possess limited specificity. This study aimed to develop a new non-invasive strategy based on urine methylation biomarker to diagnose bladder cancer effectively.
Source of
METHODS: To identify the bladder cancer specific markers, genome-wide methylation analysis was performed on 21 paired bladder tumors and normal tissues from The Cancer Genome Atlas (TCGA) cohort, and 20 paired bladder tumors and normal tissues from Sun Yat-sen Memorial Hospital (SYMH) cohort. Next, Time of Flight Mass Spectrometer (TOF-MS) analysis was performed to access markers efficiency in large cohort. We enrolled 423 patients diagnosed with bladder cancer, 82 healthy participants and 276 controls with benign diseases from SYMH cohort. DNA of 781 urine samples extracted from the urinary cells and bisulfite modificated, and methylation status was analyzed using TOF-MS. In training set, 314 urine samples were used to develop a gene classifier by LASSO regression. An additional 467 urine samples were analyzed using the 5-gene classifier for independent validation. RESULTS: We firstly identified 40 significant methylation markers in a combined analysis of TCGA cohort and SYMH cohort. 28 of 40 markers showed good concordance (87.0%) in the assessments of patient tumor tissues and urine. The TOF-MS based methylation classifier yield a good AUC of 0.915 (with a sensitivity of 89.3% and a specificity of 83.6%) in the training group. The validation group also showed an AUC of 0.903, with a sensitivity of 88.1% and a specificity of 82.4%. The methylation classifier also exhibited a significantly improved sensitivity compared to voided urine cytology and FISH. In addition, this approach could analyze 128 samples in max one time and provide clinical report less than 2 days, which facilitated doctor make decision on time.
CONCLUSIONS: TOF-MS based urine DNA methylation classifier showed high accuracy and strong diagnostic power, even in earlystage/low-grade tumor patients. Therefore, it may be used as a noninvasive fast and high-through approach for diagnosis and recurrence surveillance in bladder cancer prior to the use of cystoscopy, which would greatly reduce the burden on patients.
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